Paper41376258
SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.
Tunheim G and 11 others. APMIS, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway. Papers, record 41376258. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41376258
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| COVID-19 | Major topic |
| SARS-CoV-2 | Major topic |
| Antibodies, Viral | Major topic |
| Antibody Formation | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Immunoglobulin G | |
| Viral Load | |
| Adult | |
| Antibodies, Neutralizing | |
| Norway | |
| Aged | |
| Spike Glycoprotein, Coronavirus | |
| Longitudinal Studies | |
| Angiotensin-Converting Enzyme 2 |
Source PubMed
References35
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35086614 | Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. | Euro Surveill | 2022 | https://conductscience.org/library/papers/35086614 | PubMed |
| 2 | 35135773 | Descriptive comparison of admission characteristics between pandemic waves and multivariable analysis of the association of the Alpha variant (B.1.1.7 lineage) of SARS-CoV-2 with disease severity in inner London. | BMJ Open | 2022 | https://conductscience.org/library/papers/35135773 | PubMed |
| 3 | 32871063 | Humoral Immune Response to SARS-CoV-2 in Iceland. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32871063 | PubMed |
| 4 | 34634066 | Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. | PLoS One | 2021 | https://conductscience.org/library/papers/34634066 | PubMed |
| 5 | 32766833 | SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. | J Infect Dis | 2020 | https://conductscience.org/library/papers/32766833 | PubMed |
| 6 | 35278794 | Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. | Diagn Microbiol Infect Dis | 2022 | https://conductscience.org/library/papers/35278794 | PubMed |
| 7 | 34398806 | Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. | Immunohorizons | 2021 | https://conductscience.org/library/papers/34398806 | PubMed |
| 8 | 33658326 | Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. | Science | 2021 | https://conductscience.org/library/papers/33658326 | PubMed |
| 9 | 37273461 | Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022. | Influenza Other Respir Viruses | 2023 | https://conductscience.org/library/papers/37273461 | PubMed |
| 10 | 36585405 | Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. | NPJ Vaccines | 2022 | https://conductscience.org/library/papers/36585405 | PubMed |
| 11 | 37053201 | The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis. | PLoS One | 2023 | https://conductscience.org/library/papers/37053201 | PubMed |
| 12 | 33723411 | Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. | Nature | 2021 | https://conductscience.org/library/papers/33723411 | PubMed |
| 13 | 33890566 | Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. | Euro Surveill | 2021 | https://conductscience.org/library/papers/33890566 | PubMed |
| 14 | 36530491 | Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom. | Lancet Reg Health Eur | 2023 | https://conductscience.org/library/papers/36530491 | PubMed |
| 15 | 38111750 | Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection. | Open Forum Infect Dis | 2023 | https://conductscience.org/library/papers/38111750 | PubMed |
| 16 | 37759666 | From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/37759666 | PubMed |
| 17 | 34418980 | Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. | BMC Infect Dis | 2021 | https://conductscience.org/library/papers/34418980 | PubMed |
| 18 | 33684923 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. | Nature | 2021 | https://conductscience.org/library/papers/33684923 | PubMed |
| 19 | 33413461 | Analysis of viral load in different specimen types and serum antibody levels of COVID-19 patients. | J Transl Med | 2021 | https://conductscience.org/library/papers/33413461 | PubMed |
| 20 | 35611346 | A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. | Open Forum Infect Dis | 2022 | https://conductscience.org/library/papers/35611346 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41376258 | SARS-CoV-2 Infection With Alpha B.1.1.7 Virus Induced Higher Antibody Responses Than Earlier Non-VOC Variants During the First Waves of the COVID-19 Pandemic in Norway. | APMIS | 2025 | https://conductscience.org/library/papers/41376258 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ACE2 | 59272 | PubTator's text mining | https://conductscience.org/library/genes/59272 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41376258
GET https://conductscience.org/api/papers/v1/41376258/references?page=2